WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...

Lenacapavir, new twice-yearly HIV injection, raises hope for pill-weary patients. Discordant couples, sex workers hail ‘game ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...

The World Health Organization has suggested global release of lenacapavir, a twice-yearly injectable medication, as a powerful HIV infection-fighting medication. The historic suggestion was made ...

Lenacapavir received approval from the U.S. Food and Drug Administration (FDA) in June 2025 and has subsequently been endorsed in the updated World Health Organisation (WHO) guidelines on long-acting ...

Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.In a statement, Health ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...